Histone Deacetylase Inhibitors
    1.
    发明申请
    Histone Deacetylase Inhibitors 失效
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US20110287535A1

    公开(公告)日:2011-11-24

    申请号:US12977335

    申请日:2010-12-23

    IPC分类号: C12N5/071

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶可抑制基因表达,包括与肿瘤抑制有关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供用于治疗癌症,血液学疾病例如血红蛋白病和遗传相关代谢紊乱(例如囊性纤维化和肾上腺嗜甲基营养不良)的替代途径。

    HISTONE DEACETYLASE INHIBITORS
    2.
    发明申请
    HISTONE DEACETYLASE INHIBITORS 审中-公开
    HISTONE脱乙酰酶抑制剂

    公开(公告)号:US20110288168A1

    公开(公告)日:2011-11-24

    申请号:US12955470

    申请日:2010-11-29

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶抑制可抑制基因表达,包括与肿瘤抑制相关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供治疗癌症的替代途径,血液病症,例如血红蛋白病,遗传疾病, 亨廷顿氏病和脊髓性肌肉萎缩以及遗传相关的代谢紊乱,例如囊性纤维化和肾上腺脑白质营养不良。

    Histone deacetylase inhibitors
    4.
    发明授权
    Histone deacetylase inhibitors 有权
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US08026280B2

    公开(公告)日:2011-09-27

    申请号:US10025947

    申请日:2001-12-26

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy. Carboxylic acid-containing compounds having a terminal cyclic moiety, a carboxylic acid group, and a C3-12 hydrocarbon chain optionally containing at least one double bond, at least one triple bond, or at least one double bond and one triple bond linking the cyclic moiety and the carboxylic acid group are inhibitors of histone deacetylase.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分(例如羧酸基团)的化合物可抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶抑制可抑制基因表达,包括与肿瘤抑制相关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供用于治疗癌症,血液学疾病,例如血红蛋白病和遗传相关代谢紊乱(例如囊性纤维化和肾上腺脑白质营养不良)的替代途径。 含有末端环状部分的羧酸化合物,羧酸基团和任选含有至少一个双键的C3-12烃链,至少一个三键,或至少一个双键和一个三键,连接环状 部分和羧酸基团是组蛋白脱乙酰酶的抑制剂。

    Histone deacetylase inhibitors
    5.
    发明授权
    Histone deacetylase inhibitors 有权
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US07858664B2

    公开(公告)日:2010-12-28

    申请号:US11019303

    申请日:2004-12-23

    IPC分类号: A61K31/185

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶可抑制基因表达,包括与肿瘤抑制有关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供用于治疗癌症,血液学疾病,例如血红蛋白病和遗传相关代谢紊乱(例如囊性纤维化和肾上腺脑白质营养不良)的替代途径。

    Histone deacetylase inhibitors
    6.
    发明授权
    Histone deacetylase inhibitors 有权
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US07312247B2

    公开(公告)日:2007-12-25

    申请号:US09812945

    申请日:2001-03-27

    IPC分类号: A61K31/19

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶抑制可抑制基因表达,包括与肿瘤抑制相关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供用于治疗癌症,血液学疾病,例如血红蛋白病和遗传相关代谢紊乱(例如囊性纤维化和肾上腺脑白质营养不良)的替代途径。

    Histone deacetylase inhibitors
    7.
    发明授权
    Histone deacetylase inhibitors 失效
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US08420698B2

    公开(公告)日:2013-04-16

    申请号:US12977335

    申请日:2010-12-23

    IPC分类号: A61K31/235 A61K31/19

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶可抑制基因表达,包括与肿瘤抑制有关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供用于治疗癌症,血液学疾病例如血红蛋白病和遗传相关代谢紊乱(例如囊性纤维化和肾上腺嗜甲基营养不良)的替代途径。

    Histone deacetylase inhibitors
    8.
    发明授权
    Histone deacetylase inhibitors 有权
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US07902259B2

    公开(公告)日:2011-03-08

    申请号:US11059377

    申请日:2005-02-17

    IPC分类号: A61K31/19 C07C259/04

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶可抑制基因表达,包括与肿瘤抑制有关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供用于治疗癌症,血液学疾病例如血红蛋白病和遗传相关代谢紊乱(例如囊性纤维化和肾上腺嗜甲基营养不良)的替代途径。

    Histone Deacetylase Inhibitors
    9.
    发明申请
    Histone Deacetylase Inhibitors 审中-公开
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US20120035257A1

    公开(公告)日:2012-02-09

    申请号:US13041666

    申请日:2011-03-07

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶可抑制基因表达,包括与肿瘤抑制有关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供用于治疗癌症,血液学疾病,例如血红蛋白病和遗传相关代谢紊乱(例如囊性纤维化和肾上腺脑白质营养不良)的替代途径。

    Histone deacetylase inhibitors
    10.
    发明授权
    Histone deacetylase inhibitors 失效
    组蛋白脱乙酰酶抑制剂

    公开(公告)号:US07842727B2

    公开(公告)日:2010-11-30

    申请号:US11489519

    申请日:2006-07-20

    摘要: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, genetic disorders, e.g. Huntington's disease and spinal muscular atrophy and genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy.

    摘要翻译: 组蛋白脱乙酰酶是在活性位点具有锌的金属酶。 具有锌结合部分的化合物,例如异羟肟酸基或羧酸基可以抑制组蛋白脱乙酰酶。 组蛋白脱乙酰酶抑制可抑制基因表达,包括与肿瘤抑制相关的基因的表达。 因此,组蛋白脱乙酰酶的抑制可以提供治疗癌症的替代途径,血液病症,例如血红蛋白病,遗传疾病, 亨廷顿氏病和脊髓性肌肉萎缩以及遗传相关的代谢紊乱,例如囊性纤维化和肾上腺脑白质营养不良。